Our convictions change over time, thank you to verify that your preferences always match your expectations.

Pins are saved using cookies. Deleting them from your browser will delete your preferences.

delete all my pins


Alger on the money - Drug Renaissance

27 April 2018

Next-generation sequencing (NGS) allows for analysis of the human genome, the complete set of genetic material within a human.

The ways drugs are developed and diseases researchedhave changed markedly because of NGS. Additionally, tools associated with NGS are reducingthe costs of disease while improving the accuracy of diagnosis and the efficacy of treatment.

Sequencing Cost Per Genome Declining Rapidly


  • Since 2001 the cost of genome sequencing has declined considerably, allowing for more widespread use of these methods. As NGS technology advances and enables larger and more complex research projects, the cost of genetic analysis will continue to come down.
  • NGS has revolutionized drug development because researchers can now fully understand the effect of the human genome on disease as well as identify mutations to determine how best to treat diseases. Specifically, scientists are improving their understanding of cancer biology, discovering the causes of many heritable disorders and creating opportunities for preventive and predictive medicine.
  • NGS has only begun to unlock scientists’ understanding of biological systems. As NGS advances and more genetic data is collected, the research and development of drugs and diagnostic tools continue to accelerate.
  • To potentially capitalize on NGS, investors might consider health care technology companies that develop NGS equipment or tools as well as companies that use NGS to advance the diagnosis or treatment of diseases.

> Download Alger on the Money, A view on the U.S. Market

La Française Group provides access to the expertise of a number of asset management companies around the world. To provide you with the most relevant information, we have developed an interface to present the full range of products available for your investor profile and country of residence.

Present yourself


Your country of residence

Your language

Your profile

When navigating on our website, you agree to this policy and consent to our use of cookies in accordance with the terms of this policy. Find out more.